Literature DB >> 7637808

An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection.

T A Wynn1, A W Cheever, D Jankovic, R W Poindexter, P Caspar, F A Lewis, A Sher.   

Abstract

The harmful fibrosis which often occurs in the context of infectious disease involves the excessive deposition of connective tissue matrix, particularly collagen, and is mostly resistant to pharmacological and immunological intervention. In schistosomiasis, fibrosis is associated with the granulomatous response to parasite eggs trapped in the liver. We have previously shown that interleukin (IL)-12 administered peritoneally with eggs prevents subsequent pulmonary granuloma formation on intravenous challenge with eggs. Here we show that sensitization with eggs plus IL-12 partly inhibits granuloma formation and dramatically reduces the tissue fibrosis induced by natural infection with Schistosoma mansoni worms. These results are an example of a vaccine against parasites which acts by preventing pathology rather than infection. IL-12 is known to favour the priming of TH1 rather than Th2 cells, and the effects on fibrosis are accompanied by replacement of the Th2-dominated pattern of cytokine expression characteristic of S. mansoni infection with one dominated by Th1 cytokines. Elevated Th2 cytokine expression and fibrosis are common manifestations of a wide variety of infectious diseases and atopic disorders which might be ameliorated by vaccination with antigen and IL-12.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7637808     DOI: 10.1038/376594a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  117 in total

1.  Coadministration of interleukin 12 expression vector with antigen 2 cDNA enhances induction of protective immunity against Coccidioides immitis.

Authors:  C Jiang; D M Magee; R A Cox
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

Review 2.  Immunology of parasitic helminth infections.

Authors:  Andrew S MacDonald; Maria Ilma Araujo; Edward J Pearce
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

3.  Interleukin-12 as an adjuvant for an antischistosome vaccine consisting of adult worm antigens: protection of rats from cercarial challenge.

Authors:  R D Bungiro; M Goldberg; P K Suri; P M Knopf
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Interleukin-12 is capable of generating an antigen-specific Th1-type response in the presence of an ongoing infection-driven Th2-type response.

Authors:  L R Schopf; J L Bliss; L M Lavigne; C L Chung; S F Wolf; J P Sypek
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 5.  Fibrotic disease and the T(H)1/T(H)2 paradigm.

Authors:  Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

Review 6.  Macrophage activation governs schistosomiasis-induced inflammation and fibrosis.

Authors:  Luke Barron; Thomas A Wynn
Journal:  Eur J Immunol       Date:  2011-09       Impact factor: 5.532

Review 7.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease.

Authors:  Thomas A Wynn; Thirumalai R Ramalingam
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

Review 8.  Host responses in tissue repair and fibrosis.

Authors:  Jeremy S Duffield; Mark Lupher; Victor J Thannickal; Thomas A Wynn
Journal:  Annu Rev Pathol       Date:  2012-10-22       Impact factor: 23.472

9.  Schistosoma mansoni hemozoin modulates alternative activation of macrophages via specific suppression of Retnla expression and secretion.

Authors:  Martha Truscott; D Andrew Evans; Matt Gunn; Karl F Hoffmann
Journal:  Infect Immun       Date:  2012-10-22       Impact factor: 3.441

10.  Th1-polarizing immunization with egg antigens correlates with severe exacerbation of immunopathology and death in schistosome infection.

Authors:  L I Rutitzky; H J Hernandez; M J Stadecker
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.